Department of Health and Human Services with stylized eagle made up of silhouetted human faces C D C
Department of Health and Human Services
Centers for Disease Control and Prevention

National Institute for Occupational Safety and Health (NIOSH)
Search NIOSH NIOSH Home NIOSH Topics Site Index Databases and Information Resources NIOSH Products Contact Us

NIOSH Program Area:

Radiation Dose Reconstruction

 

Texas City Chemicals, Inc.
(Site Profile/Docket Number 112)

Location: Texas City, Texas
Also known as: American Oil Co.
                         Borden, Inc.
                         Smith-Douglass
                         Amoco Chemical Company

Program Evaluation Reports (PERs) and Program Evaluation Plans (PEPs)

NIOSH is committed to applying the best available science in dose reconstructions. In keeping with this commitment, completed cases with probabilities of causation less than 50% are reviewed as relevant new information becomes available. The results of these reviews are described in a Program Evaluation Report (PER). The PER details the effect, if any, of the new information on the completed dose reconstruction. If it appears that the new information may result in an increase in dose for a completed dose reconstruction with a probability of causation of less than 50%, NIOSH is committed to working with the Department of Labor to reopen and rework the dose reconstruction, as appropriate. A Program Evaluation Plan (PEP) describes plans for evaluating specific program details or issues.

At the current time, no PERs or PEPs specific to Texas City Chemicals, Inc. have been developed. However, we have developed PERs and PEPs that pertain to multiple sites. To view all PERs and PEPs that have been developed, please refer to the Program Evaluation Reports (PERs) and Program Evaluation Plans (PEPs) page.

Top of Page

Worker Outreach Activities

Based on a recommendation from the Advisory Board to provide workers and site experts with opportunities to participate in developing the technical documents used in dose reconstruction, NIOSH established a Worker Outreach Program.

At Worker Outreach Meetings, current and former DOE and AWE employees have opportunities to obtain information about Site Profiles, Technical Basis Documents, and Technical Information Bulletins, and to provide information for consideration and possible use in dose reconstruction. This process is valuable to ensure that the technical documents used in dose reconstruction contain correct and useful information.

Below are the Worker Outreach Activities for Texas City Chemicals, Inc.:

  • November 15, 2007
    Town Hall Meeting on Texas City Chemicals, Inc.
    Captain's Room of the Nessler Center
    2010 5th Avenue North
    Texas City, Texas

    7:00 p.m. to 9:00 p.m.

    Former workers, as well as family members, are invited and encouraged to attend.

    Purpose: This meeting is an opportunity for former workers, and their families, to hear about NIOSH's responsibilities under Part B of EEOICPA, including its dose reconstruction program and the SEC petitioning process. Please note this meeting is not an opportunity to discuss individual claim status; however, representatives from NIOSH and the Department of Labor will be available to answer general questions related to EEOICPA.

    Minutes
    this document in PDF PDF 38 KB (8 pages)

  • October 18, 2007
    Meeting with former workers
    International Union of Operating Engineers Local 564 hall
    Texas City, Texas

    Final Minutes
    2:00 p.m. meeting
    this document in PDF PDF 75 KB (23 pages)

    7:00 p.m. meeting
    this document in PDF PDF 51 KB (14 pages)

Top of Page

Advisory Board Work Group on the Use of Surrogate Data

This Work Group will consider the conditions under which "surrogate" data can be used as a valid substitute for actual data for a given site. The Work Group will seek to establish the type and importance of various parameters (e.g., type of nuclide, amounts of material, chemical and physical forms, processes, working conditions, and other such parameters) that impact on worker dose, and will consider the extent to which such parameters at one site may apply to other sites. The Work Group may also consider the extent to which theoretical considerations can be properly used to bound dosed in the absence of actual workplace measurements. The Work Group should strive to develop a policy recommendation that can be adopted by the Board regarding the use of surrogate data. This Work Group was asked to consider the application of surrogate data criteria to the Texas City Chemicals, Inc., site in relation to the SEC petition for that facility.

  • Work Group Members

    James Malcolm Melius, M.D., Dr. P.H.-Chair
    Josie Beach
    Mark Griffon
    James E. Lockey, M.D., M.S.
    Wanda I. Munn

  • Meeting Information

    • November 5, 2010
      Teleconference Meeting of the Advisory Board's Work Group on the Use of Surrogate Data

      1:00 p.m. (Eastern time)

      This meeting is open to the public, but without a public comment period. Teleconference call access is available for this meeting and it is limited only by the number of ports available. To access the meeting via the teleconference call access, you must dial 1-866-659-0537. To be automatically connected to the meeting, you will need to enter the following participant code: 9933701.

      Agenda
      this document in PDF PDF 9 KB (1 page)

      Transcript
      this document in PDF PDF 170 KB (62 pages)

      Please note that as part of the procedures and processes of the Advisory Board's Work Groups, several kinds of pre-decisional documents may be developed. These documents, which can include white papers, matrices, working drafts, etc., are distributed among the Work Group members as research and background tools to facilitate discussion and deliberation. The discussions during the above meeting may cover a pre-decisional document. Because these types of documents are pre-decisional in nature, may contain sensitive information, and may change over time, they are not posted on our Web site. These finalized, reviewed and redacted pre-decisional documents are also available to other interested parties through an appropriate Freedom of Information Act request. Requests for documents not in the public domain should be submitted to the CDC/ATSDR Freedom of Information Act Office at foiarequests@cdc.gov.

    • May 13, 2010
      Teleconference Meeting of the Advisory Board's Work Group on the Use of Surrogate Data

      1:00 p.m. (Eastern time)

      This meeting is open to the public, but without a public comment period. Teleconference call access is available for this meeting and it is limited only by the number of ports available. To access the meeting via the teleconference call access, you must dial 1-866-659-0537. To be automatically connected to the meeting, you will need to enter the following participant code: 9933701.

      Agenda
      this document in PDF PDF 45 KB (1 page)

      Transcript
      this document in PDF PDF 131 KB (69 pages)

      Please note that as part of the procedures and processes of the Advisory Board's Work Groups, several kinds of pre-decisional documents may be developed. These documents, which can include white papers, matrices, working drafts, etc., are distributed among the Work Group members as research and background tools to facilitate discussion and deliberation. The discussions during the above meeting may cover a pre-decisional document. Because these types of documents are pre-decisional in nature, may contain sensitive information, and may change over time, they are not posted on our Web site. These finalized, reviewed and redacted pre-decisional documents are also available to other interested parties through an appropriate Freedom of Information Act request. Requests for documents not in the public domain should be submitted to the CDC/ATSDR Freedom of Information Act Office at foiarequests@cdc.gov.

    • January 11, 2010
      Teleconference Meeting of the Advisory Board's Work Group on the Use of Surrogate Data

      1:00 p.m. (Eastern time)

      This meeting is open to the public, but without a public comment period. Teleconference call access is available for this meeting and it is limited only by the number of ports available. To access the meeting via the teleconference call access, you must dial 1-866-659-0537. To be automatically connected to the meeting, you will need to enter the following participant code: 9933701.

      An agenda will be provided at a later date.

      Transcript
      this document in PDF PDF 198 KB (92 pages)

      Please note that as part of the procedures and processes of the Advisory Board's Work Groups, several kinds of pre-decisional documents may be developed. These documents, which can include white papers, matrices, working drafts, etc., are distributed among the Work Group members as research and background tools to facilitate discussion and deliberation. The discussions during the above meeting may cover a pre-decisional document. Because these types of documents are pre-decisional in nature, may contain sensitive information, and may change over time, they are not posted on our Web site. These finalized, reviewed and redacted pre-decisional documents are also available to other interested parties through an appropriate Freedom of Information Act request. Requests for documents not in the public domain should be submitted to the CDC/ATSDR Freedom of Information Act Office at foiarequests@cdc.gov.

    • May 8, 2009
      Teleconference Meeting of the Advisory Board's Work Group on the Use of Surrogate Data

      1:00 p.m. (Eastern time)

      This meeting is open to the public, but without a public comment period. Teleconference call access is available for this meeting and it is limited only by the number of ports available. To access the meeting via the teleconference call access, you must dial 1-866-659-0537. To be automatically connected to the meeting, you will need to enter the following participant code: 9933701.

      Agenda
      this document in PDF PDF 6 KB (1 page)

      Transcript
      this document in PDF PDF 107 KB (59 pages)

      Please note that as part of the procedures and processes of the Advisory Board's Work Groups, several kinds of pre-decisional documents may be developed. These documents, which can include white papers, matrices, working drafts, etc., are distributed among the Work Group members as research and background tools to facilitate discussion and deliberation. The discussions during the above meeting may cover a pre-decisional document. Because these types of documents are pre-decisional in nature, may contain sensitive information, and may change over time, they are not posted on our Web site. These finalized, reviewed and redacted pre-decisional documents are also available to other interested parties through an appropriate Freedom of Information Act request. Requests for documents not in the public domain should be submitted to the CDC/ATSDR Freedom of Information Act Office at foiarequests@cdc.gov.

    • June 9, 2008
      Teleconference Meeting of the Advisory Board's Work Group on Surrogate Data

      11:30 a.m. (Eastern time)

      This meeting is open to the public, but without a public comment period. Teleconference call access is available for this meeting and it is limited only by the number of ports available. To access the meeting via the teleconference call access, you must dial 1-866-659-0537. To be automatically connected to the meeting, you will need to enter the following participant code: 9933701.

      Agenda items will be provided at a later date.

      Transcript
      this document in PDF PDF 58 KB (34 pages)

      Please note that as part of the procedures and processes of the Advisory Board's Work Groups, several kinds of pre-decisional documents may be developed. These documents, which can include white papers, matrices, working drafts, etc., are distributed among the Work Group members as research and background tools to facilitate discussion and deliberation. The discussions during the above meeting may cover a pre-decisional document. Because these types of documents are pre-decisional in nature, may contain sensitive information, and may change over time, they are not posted on our Web site. These finalized, reviewed and redacted pre-decisional documents are also available to other interested parties through an appropriate Freedom of Information Act request. Requests for documents not in the public domain should be submitted to the CDC/ATSDR Freedom of Information Act Office at foiarequests@cdc.gov.

Top of Page

Comments on Texas City Chemicals, Inc., Documents

How to Submit Comments
Comments on Texas City Chemicals, Inc., documents can be submitted to the NIOSH Docket Officer electronically by e-mail at NIOCINDOCKET@cdc.gov or printed comments can be mailed to NIOSH Docket Office, Robert A. Taft Laboratories, MS-C34, 1090 Tusculum Avenue, Cincinnati, OH 45226. Please include the Site Profile/Docket Number (112) on all comments.

Comments Received

Top of Page

Special Exposure Cohort Petition Information for Texas City Chemicals, Inc.

Top of Page

Previous Versions of Texas City Chemicals, Inc. Documents

Top of Page

Page last updated: March 10, 2011
Page last reviewed: August 10, 2013
Content Source: National Institute for Occupational Safety and Health (NIOSH) Division of Compensation Analysis and Support